PROCEPT BioRobotics appoints Elisabeth Sandoval to Board of Directors

PROCEPT BioRobotics Corp

Board expanded from eight to nine members; Sandoval appointed as Class I director effective Oct. 21, 2021.
Sandoval is a healthcare executive with prior roles at Allergan (20+ years) and as CCO of Kythera Biopharmaceuticals and Alder Biopharmaceuticals.
She will receive a restricted stock unit award valued at $200,000, vesting over three years.
Sandoval also serves on boards of Intersect ENT, Satsuma Pharmaceuticals, Vyne Therapeutics, and Alastin Skincare.
CEO Reza Zadno cited her commercial expertise to accelerate Aquablation therapy adoption for BPH.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elisabeth Sandoval

Director

PRCT · PROCEPT BioRobotics Corp

Effective: 2021-10-21
Filed: October 26, 2021, 7:59 PM ET

Effective October 21, 2021, the Board of Directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) increased the number of directors on the Board from eight to nine and appointed Elisabeth Sandoval as a Class I director of the Company, with such appointment taking effect immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elisabeth Sandoval was appointed as Director at PROCEPT BioRobotics Corp.

Action: appointed
Role: Director

Exact text from the filing

Effective October 21, 2021, the Board of Directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) increased the number of directors on the Board from eight to nine and appointed Elisabeth Sandoval as a Class I director of the Company, with such appointment taking effect immediately.

View on SEC.gov

PROCEPT BioRobotics Corp filing history →

Source: SEC EDGAR

accession 0001588978-21-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.